Myriad Genetics Inc

MYGNNASDAQ • USD
ThemeGenomics & Precision Med.›Genetic Testing & Diagnostics
5.66 USD
↘ 0.02 (0.35%)AT CLOSE (03:59 PM EST)
5.60
↘ 0.06 (1.06%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
5.60
↘ 0.06 (1.06%)
🔴Market: CLOSED

MYGN is currently priced at $5.66. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation side, MYGN appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Nov 13, 2026.

Open?$5.71
High?$5.71
Low?$5.51
Prev. Close?$5.68
Volume?1.1M
Avg. Volume?2.7M
VWAP?$5.63
Rel. Volume?0.39x
Bid / Ask
Bid?$5.60 × 100
Ask?$5.75 × 100
Spread?$0.15
Midpoint?$5.68
Valuation & Ratios
Market Cap?542.9M
Shares Out?95.6M
Float?92.1M
Float %?96.2%
P/E Ratio?N/A
P/B Ratio?2.02
EPS?-$1.35
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Themes
Healthcare - Genomics & Precision Medicine›Genetic Testing & DiagnosticsHealthcare - Oncology›Cancer Diagnostics & Biomarkers
Employees
2.7K
Market Cap
544.8M
Industry
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Website
www.myriad.com
Listed
1995-10-06
Address
322 NORTH 2200 WEST
SALT LAKE CITY, UT 84116
Phone: 801-584-3600
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
1
Momentum?
50
Short Sent.?
51
Piotroski F-Score?1/9Weak
Altman Z-Score?-0.94Distress
Confidence?62%Moderate
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?9.16%Elevated
Short Interest?8.4M
Days to Cover?2.0
Free Float92.1M
Avg Daily Volume4.2M
Settlement Date2026-10-30
Financial Health
Current Ratio?1.98Adequate
Quick Ratio?1.77Adequate
Cash Ratio?0.78Adequate
Debt/Equity?0.45Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
74
2.02CHEAP▾
P/S?
Peers
100
S&P
92
0.68CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-9.8CHEAP▾
EV/Sales?
Peers
100
S&P
97
0.69CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-48.0%WEAK▾
ROA?
S&P
3
-21.2%WEAK▾
Cash Flow & Enterprise
FCF?$-24600000
Enterprise Value?$556.9M
Fundamentals ratios updated end of day
MarketsMoversWatchlist